Upload
others
View
0
Download
0
Embed Size (px)
Citation preview
hERG1channels:froman2targetstonoveltherapeu2ctargetsinoncology
AnnarosaArcangeli1,AndreaBecche-2,OliviaCrociani,MassimoD’Amico1,LucaGasparoli1,MarikaMasselli,SerenaPillozzi1,KennethMugridge3andWolfgangTiedke3.
1DepartmentofExperimentalPathologyandOncology,UniversityofFlorenceandIsPtutoToscanoTumori(ITT),Florence,Italy;2DepartmentofBiotechnologyandBiosciences,
UniversityofMilanoBicocca,Milano,Italy;3BlackSwanPharmaGmbH,Leipzig,Germany.
Disclosures
• Noconflictofinteresttodeclare
hERG1POTASSIUMCHANNELS
SeveraldrugsblockhERG1channels
drug‐inducedLQT2
ANTITARGET
SpecifichERG1blockersE4031WAY123,398
‐ AcutemyeloidandlymphoblasPcleukemiasHofmannetal.,J.Biol.Chem.,2001;Pillozzietal.,Leukemia,2002;Pillozzietal.,Blood,2007;Pillozzietal.,Blood,2011
‐ EndometrialCancersCherubinietal.,Br.J.Cancer,2000
‐ NeuroblastomasArcangelietal.,J.CellBiol.,1993;Arcangelietal.,J.Physiol.,1995;Arcangelietal.,Eur.J.Neurosci,1997;Crocianietal.,Mech.Devel.,2000;Crocianietal.,J.Biol.Chem.,2003
‐ ColorectalandGastricCancersLastraiolietal.,CancerRes.2004;Lastraiolietal.,J.Cell.Physiol.,2006.
‐ GlioblastomaMasietal.,Br.J.Cancer,2005.
hERG1isoverexpressedinseveraltypesofhumancancers
hERG1regulatesdifferentbiologicalfunc2onsincancercells
• Cellprolifera2on(myeloidleukemias)
• Drug‐inducedapoptosis(lymphoblas2cleukemias)• Tumorcellinvasionandmetasta2cspread(colorectalcancers)
• Trans‐endothelialmigra2onandinvasionofextra‐medullaryorgans(myeloidleukemias)
• VEGF‐Asecre2onandangiogenesis(astrocytomas;gastricandcolorectalcancers)
hERG1:
newtargetinoncology?
Adversecardiaceffects!
Differencesbetween“cardiac”and“tumour”hERG1
• Biophysical• Molecular
• FuncPons
BiophysicalcharacterisPcsofhERG1channels
I(K)ERGquicklyinac2vatesaferopeningatposi2vepoten2alsInac2va2onisfasterthanac2va2onRecoveryfrominac2va2onisfasterthandeac2va2on
Membranepoten2al
• Intheheart:hERG1=Ikr• hERG1channelsac2vateslowlyandinac2vaterapidlyduringtheini2alphasesofthecAP;asrepolariza2onbegins,hERG1channelsrapidlyrecoverfrominac2va2onandgenerateanappreciableoutwardcurrent.• Incancercells:• hERG1channelsexibitasignificantsteady–stateconductanceatmembranepoten2alsaround‐40mV
Molecularcharacteris2csofhERG1incancercells
A
Func2onsofhERG1incancercells
hERG1channelsco‐assemblewithintegrinsandmodulateintegrin‐dependentsignalling.
PotenPalapproachestoimprovetheefficacyandsafetyofhERG1channel
targePnginoncology:
‐Useof“non‐torsadogenic”hERG1blockers(e.g.erythromycin,ser2ndole).‐ UseofcompoundswhichbindhERG1channelsintheopenstate(D‐Roscovi2ne).‐ Use/developmentofcompoundswhichselec2velyinhibittumour‐specifichERG1isoform(s)‐Developmentofcompounds(an2bodies,pep2des)whichdisassembletheionchannel/integrincomplex.
PotenPalapproachestoimprovetheefficacyandsafetyofhERG1channel
targePnginoncology:
‐Useof“non‐torsadogenic”hERG1blockers(e.g.erythromycin,ser2ndole).‐ UseofcompoundswhichbindhERG1channelsintheopenstate(D‐Roscovi2ne).‐ Use/developmentofcompoundswhichselec2velyinhibittumour‐specifichERG1isoform(s)‐Developmentofcompounds(an2bodies,pep2des)whichdisassembletheionchannel/integrincomplex.
ErythromycinSer2ndole
State‐dependentblockofHERGpotassiumchannelsbyR‐roscovi)ne:
implicaPonsforcancertherapy
GanapathiSBetal.,AmJPhysiolCellPhysiol296:C701–C710,2009.
R‐RoscoviPne
SerenaPillozzi
SURVIVAL (ILK, AKT)
β1/hERG1/CXCR4 complex
Thecomplexisrelevanttodrivesurvivalsignals
whichistheeffectofblockinghERG1channelsondrug‐inducedapoptosis?
apop
to2ccells(%
)(Ann
exin+/PI‐)
TheaddiPonofhERG1blockersshortcomestheprotecPveeffectofBoneMarrowStromalCellsonDoxorubicin(Prednisone,Methotrexate,L‐asparaginase)‐induced
apoptosis
PrimaryB‐ALL
E4031synergizeswithchemotherapeu2cdrugs……onMSC
EffectsofthehERG1blockerE4031invivo
E4031hasatherapeu2ceffectinvivoonB‐ALL(697cells):increasein
survival
E4031hasatherapeu2ceffectinvivoonB‐ALL(cor2costeroid‐resistantREH
cells)
NontorsadogenichERG1blockers(ErythromycinandSer2ndole)andR‐
Roscovi2nehavethesameeffectsofE4031
EffectsofErythromycinonprimaryB‐ALL
PotenPalapproachestoimprovetheefficacyandsafetyofhERG1channel
targePnginoncology:
‐Useof“non‐torsadogenic”hERG1blockers(e.g.erythromycin,ser2ndole).‐ UseofcompoundswhichbindhERG1channelsintheopenstate(D‐Roscovi2ne).‐ Use/developmentofcompoundswhichselec2velyinhibittumour‐specifichERG1isoform(s)‐Developmentofcompounds(an2bodies,pep2des)whichdisassembletheionchannel/integrincomplex.
Leipzig,Germany
W.Tiedke
EffectsofCD‐160130onprolifera2onofleukemiacelllinesandhERG1A/hERG1B‐expressingcells:LD50
values(comparisonwithE4031)
MassimoD’AmicoLucaGasparoli
CD‐160130preferen2allyinhibitsthehERG1Bisoform(comparisonwithE4031)
FLG29.1CellsIC501.2µM
CD‐160130preferen2allyblockshERG1Bisoform
…alsoinleukemiacells
CD‐160130issynergicwithFludarabineonapoptosisofMEC1cells(CLL)onMSC
• LessharmfulcompoundscanbedevelopedwhichblockhERG1
channelsincancercells.
Acknowledgements:
Dr.AndreaBecche-UniversityofMilanoBicocca
Prof.EnzoWanke